RecruitingNCT04020536
Real World Study of Classic Infectious Disease
Sponsor
Huashan Hospital
Enrollment
10,000 participants
Start Date
May 13, 2020
Study Type
OBSERVATIONAL
Conditions
Summary
This study aimed to collect and analyze clinical specimens of patients with classic infectious diseases in the real world. To investigate the epidemiological distribution of classic infectious diseases (brucellosis, epidemic hemorrhagic fever, kala-azar) and treatment options suitable for China.
Eligibility
Min Age: 18 YearsMax Age: 75 Years
Inclusion Criteria6
- Brucellosis： Patients with any of the following confirmed the evidence.
- sample culture: Brucella;
- Specific antigen or antibody (IgG or IgM) positive. epidemic hemorrhagic fever：
- specific antibody positive 2 Hantavirus RNA positive kala-azar：
- latent infection: rK39 antibody positive
- patients with the following evidence of kala-azar diagnosis: 1) bone marrow, spleen puncture sample culture: Leishmania; 2) bone marrow, spleen puncture sample smear: Leishmania; 3) clinical symptoms, history of exposure or epidemiology, and positive screening test (rK39 positive)
Exclusion Criteria4
- Patient history data is incomplete
- HIV antibody positive and AIDS patients
- Patients who participated in other clinical trials during the same period.
- Pregnant, lactating women or women of childbearing age who are ready to conceive.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGAntibiotics
Local doctors prescribe available antibiotics to the patients according to the guideline and patients' condition
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04020536